Search clinical trials for: paliperidone extended release

Total 5452 results

Janssen-Cilag International NV

Completed

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia (PERFlexS)

Schizophrenia

France, United Kingdom, Belgium, Germany, Spain, Portugal, Bulgaria, Serbia, Switzerland, Israel, Finland, Greece, Sweden, Russian Federation, Netherlands, Denmark, Hungary, Lithuania, Latvia, Croatia, Turkey, Poland
Calo Psychiatric Center

Completed

Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment

Schizophrenics
Wei Hao

Completed

An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence

Methamphetamine Dependence

China
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

Schizophrenia

United States
Janssen Research & Development, LLC

Completed

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

Psychotic Disorders | Schizophrenia | Schizophrenic Disorders | Dementia Praecox

United States, Belgium, Poland, Bulgaria, India, Romania, Russian Federation, Ukraine, Korea, Republic of, Estonia, Finland
Johnson & Johnson Taiwan Ltd

Terminated

A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia

Schizophrenia

Taiwan
Janssen Cilag N.V./S.A.

Completed

IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation

Psychomotor Agitation | Acute Disease

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

Bipolar Disorder

United States, China, Germany, Bulgaria, Costa Rica, France, India, Malaysia, Panama, Poland, Romania, Russian Federation, Serbia, South Africa, Turkey, Ukraine
Wei Hao

Completed

A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis

Methamphetamine Dependence

China
Janssen Research & Development, LLC

Completed

An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia

Schizophrenia

China
Janssen Korea, Ltd., Korea

Completed

Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants (PASS)

Schizophrenia

Korea, Republic of
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

Mood Disorders | Bipolar Disorder

United States, Taiwan, Russian Federation, Turkey, Ukraine, Greece, Korea, Republic of, Lithuania
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia

Schizophrenia

United States, Taiwan, India
Janssen Korea, Ltd., Korea

Completed

Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission (PERFECT)

Schizophrenia

Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Schizoaffective Disorder | Psychotic Disorder

United States, India, Malaysia, Romania, Korea, Republic of, Philippines
Janssen Pharmaceutica

Completed

Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia

Schizophrenia

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

Schizophrenia

United States, India, Romania, Russian Federation, Ukraine
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder

Psychotic Disorders | Schizophrenia | Bipolar Disorder

United States
Janssen Korea, Ltd., Korea

Completed

Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants (Power)

Schizophrenia

Korea, Republic of
Janssen Korea, Ltd., Korea

Completed

PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia (PANDORA)

Schizophrenia

Korea, Republic of
Janssen-Cilag G.m.b.H

Terminated

A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls

Schizophrenia

Germany
Johnson & Johnson Taiwan Ltd

Completed

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia

Schizophrenia
Johnson & Johnson Taiwan Ltd

Completed

Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER)

Schizophrenia
Johnson & Johnson Taiwan Ltd

Completed

A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia

Schizophrenia
Janssen-Cilag Farmaceutica Ltda.

Completed

A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone

Schizophrenia

Brazil
Janssen-Cilag Turkey

Completed

A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia

Schizophrenia

Turkey
Xian-Janssen Pharmaceutical Ltd.

Completed

A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia

Schizophrenia
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia (PERTAIN)

Schizophrenia

Poland, Israel, Romania, Germany, Lithuania, Croatia, France
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Schizoaffective Disorder | Psychotic Disorder
Janssen Research & Development, LLC

Completed

An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia

Schizophrenia

Ukraine, United States, Spain, India, Romania, Russian Federation, Slovakia
Janssen-Cilag S.p.A.

Completed

Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years

Schizophrenia
Janssen-Cilag, S.A.

Completed

Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia (PERFLEX)

Schizophrenia

Colombia, Argentina
Janssen-Cilag Ltd.,Thailand

Completed

Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants (PRESENT)

Schizophrenia

Thailand
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men

Epilepsy | Schizophrenia
Chonbuk National University Hospital
AstraZeneca; Sanofi-Synthelabo; Janssen Korea, Ltd., Korea; Korea Otsuka Pharmaceutical...

Completed

Different Safety Profile of Risperidone and Paliperidone Extended-release

Schizophrenia

Korea, Republic of
Janssen Pharmaceutica

Completed

A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

A Long-Term Study of JNS007ER in Patients With Schizophrenia

Schizophrenia
Chonnam National University Hospital
Janssen Korea, Ltd., Korea; Ministry of Health, Republic of Korea

Completed

Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia

Schizophrenia

Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder

Mood Disorders | Bipolar Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations

Schizophrenia | Schizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia

Schizophrenia

3

Subscribe